Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 9;7(9):1831–1848. doi: 10.1182/bloodadvances.2022007267

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 3. — Longitudinal monitoring of FVIII-specific antibodies and FVIII inhibitors in HIPS-ITI patients 3 and 4 during HIPS and HIPS-ITI. (A,C) FVIII-specific antibody titers (IgG1, IgG2, IgG3, IgG4, IgA, IgM as indicated) and FVIII inhibitors (BU/mL) for HIPS-ITI patients 3 (A) and 4 (C). The red dotted line represents the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL). The yellow star marks the initiation of ITI treatment at ED12 (HIPS-ITI patient 3) and ED13 (HIPS-ITI patient 4). The continuous vertical line indicates the end of HIPS and the start of HIPS-ITI. (B,D) Mean K_A for FVIII-specific antibodies differentiated for individual IgG subclasses/Ig isotypes and FVIII inhibitors (BU/mL) for HIPS-ITI patients 3 (B) and 4 (D). Data for apparent K_As include the 95% CIs for up to 2 affinity clusters for each IgG subclass and for IgA (dark colors: cluster 1; light colors: cluster 2). The red dotted line represents the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL). The asterisks mark antibodies with apparent affinities that were too high (K_As > 10¹¹ M⁻¹) to be assessed. Therefore, their apparent K_As were reported as 10¹¹ M⁻¹. The yellow star marks the initiation of ITI treatment at ED12 (HIPS-ITI patient 3) and ED13 (HIPS-ITI patient 4). The continuous vertical line indicates the end of HIPS and the start of HIPS-ITI. ∗IgG1 cluster 1.

Figure 3. — Longitudinal monitoring of FVIII-specific antibodies and FVIII inhibitors in HIPS-ITI patients 3 and 4 during HIPS and HIPS-ITI. (A,C) FVIII-specific antibody titers (IgG1, IgG2, IgG3, IgG4, IgA, IgM as indicated) and FVIII inhibitors (BU/mL) for HIPS-ITI patients 3 (A) and 4 (C). The red dotted line represents the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL). The yellow star marks the initiation of ITI treatment at ED12 (HIPS-ITI patient 3) and ED13 (HIPS-ITI patient 4). The continuous vertical line indicates the end of HIPS and the start of HIPS-ITI. (B,D) Mean K_A for FVIII-specific antibodies differentiated for individual IgG subclasses/Ig isotypes and FVIII inhibitors (BU/mL) for HIPS-ITI patients 3 (B) and 4 (D). Data for apparent K_As include the 95% CIs for up to 2 affinity clusters for each IgG subclass and for IgA (dark colors: cluster 1; light colors: cluster 2). The red dotted line represents the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL). The asterisks mark antibodies with apparent affinities that were too high (K_As > 10¹¹ M⁻¹) to be assessed. Therefore, their apparent K_As were reported as 10¹¹ M⁻¹. The yellow star marks the initiation of ITI treatment at ED12 (HIPS-ITI patient 3) and ED13 (HIPS-ITI patient 4). The continuous vertical line indicates the end of HIPS and the start of HIPS-ITI. ∗IgG1 cluster 1.